Market Overview

UPDATE: Deutsche Bank Initiates Coverage on Idenix Pharmaceuticals with Buy Rating, $7 PT

Related IDIX
What Investors Are Watching For In Regulus Therapeutics' Next Data Release
Wall Street's Hall Of Fame (And Hall Of Shame): The Best And Worst Analyst Recommendations Of 2014

In a report published Wednesday, Deutsche Bank initiated coverage on Idenix Pharmaceuticals (NASDAQ: IDIX) with a Buy rating and $7.00 price target.

Deutsche Bank noted, “We believe that the risk/reward on IDIX shares heading into 2013 is very favorable. The current share price does not reflect pipeline development, and we believe that we think that IDIX has various shots (with nukes, NS5A, or both) on goal that could lead to reemergence of HCV pipeline in next 12 mos. We think investors will assign more value over 2013. Our base case assumes a nuke/NS5A combo probability adjusted launching in 2016 and a low royalty in US from other nuke developers.”

Idenix Pharmaceuticals closed on Tuesday at $4.52.

Latest Ratings for IDIX

Jun 2014UBSDowngradesBuyNeutral
Jun 2014BairdUpgradesUnderperformNeutral
Jan 2014JMP SecuritiesDowngradesMarket PerformMarket Underperform

View More Analyst Ratings for IDIX
View the Latest Analyst Ratings

Posted-In: Deutsche BankAnalyst Color Initiation Analyst Ratings


Related Articles (IDIX)

View Comments and Join the Discussion!

Get Benzinga's Newsletters